| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 2,061 | 7,197 | 17,151 | 28,301 |
| Research and development, net | 21,527 | 24,475 | 23,265 | 29,579 |
| General and administrative | 9,465 | 14,028 | 10,398 | 10,338 |
| Total operating expenses | 30,992 | 38,503 | 33,663 | 39,917 |
| Loss from operations | -28,931 | -31,306 | -16,512 | -11,616 |
| Gain (loss) from foreign currency | NaN | 700 | -170 | -127 |
| Finance income, net | 1,932 | NaN | NaN | NaN |
| Other income (expense) | 35 | 1,523 | 3,234 | 2,567 |
| Net loss before income taxes | NaN | -29,083 | -13,448 | -9,176 |
| Provision (benefit) for income taxes | NaN | NaN | NaN | 4 |
| Net loss | -26,964 | -29,079 | -13,448 | -9,180 |
| Comprehensive loss | -26,964 | -29,079 | -13,448 | -9,180 |
| Basic EPS | -0.95 | -1.034 | -0.49 | -0.34 |
| Diluted EPS | -0.95 | -1.034 | -0.49 | -0.34 |
| Basic Average Shares | 28,421,000 | 28,120,000 | 27,188,000 | 27,129,000 |
| Diluted Average Shares | 28,421,000 | 28,120,000 | 27,188,000 | 27,129,000 |
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)